Evidence map›Paper›PMID 38555305›Full record

ArticleNature communications2024

Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies.

Saeed Daneshmandi, Jee Eun Choi, Qi Yan, Cameron R MacDonald, Manu Pandey, Mounika Goruganthu, Nathan Roberts, Prashant K Singh, Richard M Higashi, Andrew N Lane and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Suppression of pre-B cell colony formation by catecholamine oxidation.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Neuro-immune cross-talk in cancer.Nature reviews. Cancer · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Saeed DaneshmandiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Jee Eun ChoiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Qi YanDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Cameron R MacDonaldDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Manu PandeyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Mounika GoruganthuDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Nathan RobertsDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Prashant K SinghDepartment of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Richard M HigashiDepartment of Toxicology and Cancer Biology, Markey Cancer Center, Center for Environmental and Systems Biochemistry (CESB), Lexington, KY, USA.ORCID http://orcid.org/0000-0002-3256-0622
Andrew N LaneDepartment of Toxicology and Cancer Biology, Markey Cancer Center, Center for Environmental and Systems Biochemistry (CESB), Lexington, KY, USA.ORCID http://orcid.org/0000-0003-1121-5106
Teresa W-M FanDepartment of Toxicology and Cancer Biology, Markey Cancer Center, Center for Environmental and Systems Biochemistry (CESB), Lexington, KY, USA.
Jianmin WangDepartment of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.ORCID http://orcid.org/0000-0001-7527-0409
Philip L McCarthyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.ORCID http://orcid.org/0000-0002-9577-3879
Elizabeth A RepaskyDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA.
Hemn MohammadpourDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, NY, USA. hemn.mohammadpour@roswellpark.org.ORCID http://orcid.org/0000-0002-0158-7283
Roswell Park Comprehensive Cancer Center · USMarkey Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGYT32CA085183 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Scott I. Abrams · 2001 to 2026
$3.1M
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitorsR01CA205246 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI REPASKY, ELIZABETH A · 2018 to 2022
$2.8M
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) ResponsesR00HL155792 · NHLBI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOHAMMADPOUR, HEMN · 2022 to 2024
$747k
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GvT) ResponsesK99HL155792 · NHLBI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOHAMMADPOUR, HEMN · 2021 to 2022
$236k
The impact of chronic stress on radiation induced cell death and the anti-tumor immune responseF30CA265127 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MACDONALD, CAMERON RIKER · 2021 to 2024
$169k
NCI NIH HHS F30 CA265127NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA205246NCI NIH HHS T32 CA085183NHLBI NIH HHS K99 HL155792NHLBI NIH HHS R00 HL155792
6 · The paper itself

Abstract

Myeloid derived suppressor cells (MDSCs) are key regulators of immune responses and correlate with poor outcomes in hematologic malignancies. Here, we identify that MDSC mitochondrial fitness controls the efficacy of doxorubicin chemotherapy in a preclinical lymphoma model. Mechanistically, we show that triggering STAT3 signaling via β2-adrenergic receptor (β2-AR) activation leads to improved MDSC function through metabolic reprograming, marked by sustained mitochondrial respiration and higher ATP generation which reduces AMPK signaling, altering energy metabolism. Furthermore, induced STAT3 signaling in MDSCs enhances glutamine consumption via the TCA cycle. Metabolized glutamine generates itaconate which downregulates mitochondrial reactive oxygen species via regulation of Nrf2 and the oxidative stress response, enhancing MDSC survival. Using β2-AR blockade, we target the STAT3 pathway and ATP and itaconate metabolism, disrupting ATP generation by the electron transport chain and decreasing itaconate generation causing diminished MDSC mitochondrial fitness. This disruption increases the response to doxorubicin and could be tested clinically.

Indexed as

Hematologic NeoplasmsMyeloid-Derived Suppressor CellsSuccinatesAdenosine TriphosphateDoxorubicinGlutamineHumansAdenosine TriphosphateDoxorubicinGlutamineitaconic acidSuccinates

Identifiers

PMID38555305
PMCPMC10981707
OpenAlexW4393338106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.